PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data
Blockers of programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) are being actively studied in non-small-cell lung cancer (NSCLC). By expressing PD-L1 ligand on the surface of tumor cells and binding to the PD-1 receptor on T, B, and NK cells, tumors can bypass immunosurveillance [1]. In the field of lung cancer, anti-PD-1/PD-L1 antibodies have produced clinical response and survival improvement in advanced NSCLC in clinical trials, and two anti-PD-1 antibodies [2 –4], nivolumab and pembolizumab, have been approved by the FDA for the treatment of advanced NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Young Wha Koh, Su Jin Lee, Jae-Ho Han, Seokjin Haam, Joonho Jung, Hyun Woo Lee Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Study